CLIPS: UPMC Health Plan and Biogen Announce Groundbreaking Value-Based Agreement for Multiple Sclerosis Treatments

UPMC has entered into a value-based agreement with Biogen for Tecfidera® and Avonex®, two specialty medications used to treat patients with relapsing forms of multiple sclerosis (MS). The contract is the first of its kind, and reimbursements will be linked to MS-reported disability progression measures in a real-world population. “This new contract continues the innovative work that we are leading at the UPMC Center for Value-Based Pharmacy Initiatives to change the paradigm around how we pay for medications by utilizing outcome measures that clinically and financially align all of our stakeholders,” said Chronis Manolis, RPh, chief pharmacy officer at UPMC Health Plan.